Clinical Trial Detail

NCT ID NCT00601003
Title Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Giselle Sholler
Indications

medulloblastoma

neuroblastoma

Therapies

Cyclophosphamide + Nifurtimox + Topotecan

Age Groups: adult child

No variant requirements are available.